Iovance reports $444M net loss for 2023; Amtagvi approved and launched Feb 2024

IOVANCE BIOTHERAPEUTICS, INC.

2023-FY EPS reported -$1.89 revenue$1,189,000

FDA approved Amtagvi (lifileucel) on Feb 16, 2024 — first T cell therapy for a solid tumor (advanced melanoma).
Net loss $444.0M ($1.89/share) for 2023 vs $395.9M ($2.49/share) in 2022; revenue $1.2M (first Proleukin sales).
Cash $346.3M at Dec 31, 2023; post Feb 2024 equity raise ~$485.2M, expected to fund operations into H2 2025.
~30 U.S. ATCs onboarded; ~50 expected by May 2024; at least 20 patients in process since approval.
MAA for EU expected H1 2024; UK and Canada submissions H2 2024; clinical hold on IOV-LUN-202 NSCLC trial.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

IOVANCE BIOTHERAPEUTICS, INC. reported fourth quarter ended December 31, 2023 results: net income Net loss for the fourth quarter ended December 31, 2023, was $116.4 million, EPS $0.45 per share.

Period: fourth quarter ended December 31, 2023
Net income: Net loss for the fourth quarter ended December 31, 2023, was $116.4 million
EPS: $0.45 per share
Result: reported results

Exact text from the filing

Net loss for the fourth quarter ended December 31, 2023, was $116.4 million, or $0.45 per share, compared to a net loss of $105.3 million, or $0.64 per share, for the fourth quarter ended December 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

IOVANCE BIOTHERAPEUTICS, INC. reported year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $444.0 million, EPS $1.89 per share.

Period: year ended December 31, 2023
Net income: Net loss for the year ended December 31, 2023 was $444.0 million
EPS: $1.89 per share
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2023 was $444.0 million, or $1.89 per share, compared to a net loss of $395.9 million, or $2.49 per share, for the year ended Dec

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

IOVANCE BIOTHERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-028704

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.